Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast [Yahoo! Finance]
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Yahoo! Finance
than a decade after launch amid increasing competition and says it “is impressive and difficult to ignore.” Korlym (mifepristone) is a prescription medicine used to treat high blood sugar (hyperglycemia) caused by high cortisol levels in the blood (hypercortisolism) in adults with endogenous Cushing syndrome who have type 2 diabetes mellitus or glucose intolerance and who cannot have surgery or for whom surgery has failed. Cushing syndrome is a hormonal disorder that occurs when the body has too much cortisol, a hormone that helps the body respond to stress. Truist analyst notes approximately 20K Cushing's disease (pituitary adenoma) patients in the U.S., of which ~10K are adequately managed with surgical resection of the pituitary adenoma. Medical management is recommended for the remaining 10K. Therefore, there's still significant room for growth, with just ~2,000 hypercortisolism patients currently on Korlym. In June, Teva Pharmaceuticals Inc. (NYSE: TEVA ) reportedly sue
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call [Yahoo! Finance]Yahoo! Finance
- Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference CallBusiness Wire
- Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.MarketBeat
- Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock? [Yahoo! Finance]Yahoo! Finance
- Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Canaccord Genuity Group Inc. from $78.00 to $130.00. They now have a "buy" rating on the stock.MarketBeat
CORT
Earnings
- 10/30/24 - Beat
CORT
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/14/25 - Form 5
- 2/13/25 - Form 4
- CORT's page on the SEC website